AU3888793A - Novel medicament - Google Patents

Novel medicament

Info

Publication number
AU3888793A
AU3888793A AU38887/93A AU3888793A AU3888793A AU 3888793 A AU3888793 A AU 3888793A AU 38887/93 A AU38887/93 A AU 38887/93A AU 3888793 A AU3888793 A AU 3888793A AU 3888793 A AU3888793 A AU 3888793A
Authority
AU
Australia
Prior art keywords
novel medicament
medicament
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU38887/93A
Inventor
Ole Kirk
Lone Pridal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of AU3888793A publication Critical patent/AU3888793A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU38887/93A 1992-03-19 1993-03-18 Novel medicament Abandoned AU3888793A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK92364A DK36492D0 (en) 1992-03-19 1992-03-19 PREPARATION
DK364/92 1992-03-19

Publications (1)

Publication Number Publication Date
AU3888793A true AU3888793A (en) 1993-10-21

Family

ID=8092684

Family Applications (1)

Application Number Title Priority Date Filing Date
AU38887/93A Abandoned AU3888793A (en) 1992-03-19 1993-03-18 Novel medicament

Country Status (6)

Country Link
EP (1) EP0631504A1 (en)
JP (1) JPH07504669A (en)
KR (1) KR950700754A (en)
AU (1) AU3888793A (en)
DK (1) DK36492D0 (en)
WO (1) WO1993018785A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU671117B2 (en) * 1992-06-15 1996-08-15 Scios Inc. Glucagon-like peptide and insulinotropin derivatives

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614492A (en) * 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US6284727B1 (en) 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
HU225496B1 (en) * 1993-04-07 2007-01-29 Scios Inc Pharmaceutical compositions of prolonged delivery, containing peptides
DE19530865A1 (en) * 1995-08-22 1997-02-27 Michael Dr Med Nauck Active ingredient and agent for parenteral nutrition
US6852690B1 (en) 1995-08-22 2005-02-08 Amylin Pharmaceuticals, Inc. Method and composition for enhanced parenteral nutrition
CA2468374C (en) 1996-08-30 2010-12-21 Novo-Nordisk A/S Glp-1 derivatives
JP2001525371A (en) 1997-12-05 2001-12-11 イーライ・リリー・アンド・カンパニー GLP-1 preparation
AU2610699A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S Derivatives of glp-1 analogs
EP1062240B1 (en) 1998-02-27 2010-04-28 Novo Nordisk A/S N-terminally modified glp-1 derivatives
ATE466026T1 (en) 1998-02-27 2010-05-15 Novo Nordisk As DERIVATIVES OF GLP-1 AND EXENDIN WITH EXTENDED DURATION PROFILE
EP1056775B1 (en) 1998-02-27 2010-04-28 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
EP1306091A3 (en) 1998-07-31 2003-05-21 Novo Nordisk A/S Stimulation of beta cell proliferation
AR022368A1 (en) * 1998-08-28 2002-09-04 Lilly Co Eli PROCEDURE FOR MANAGING INSULINOTROPIC PEPTIDES
EP1666054A1 (en) * 1998-08-28 2006-06-07 Eli Lilly & Company Method for administering insulinotropic peptides
US6720407B1 (en) 1998-08-28 2004-04-13 Eli Lilly And Company Method for administering insulinotropic peptides
WO2000037098A1 (en) * 1998-12-22 2000-06-29 Eli Lilly And Company Shelf-stable formulation of glucagon-like peptide-1
JP2003519664A (en) * 2000-01-11 2003-06-24 ノボ ノルディスク アクティーゼルスカブ Transepithelial delivery of GLP-1 derivatives
ATE309818T1 (en) 2000-03-08 2005-12-15 Novo Nordisk As LOWERING SERUM CHOLESTEROL
EP1412384B1 (en) 2001-06-28 2007-12-26 Novo Nordisk A/S Stable formulation of modified glp-1
EP2261250B1 (en) 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin fusion proteins
JP2007524592A (en) 2003-06-03 2007-08-30 ノボ・ノルデイスク・エー／エス Stabilized pharmaceutical peptide composition
TW200526254A (en) 2003-09-19 2005-08-16 Novo Nordisk As Novel GLP-1 derivatives
CA2545034C (en) 2003-11-20 2013-03-05 Novo Nordisk A/S Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
WO2007065156A2 (en) * 2005-12-02 2007-06-07 Nastech Pharmaceutical Company Inc. Pharmaceutical formulation for increased epithelial permeability of glucose-regulating peptide
US20050143303A1 (en) * 2003-12-26 2005-06-30 Nastech Pharmaceutical Company Inc. Intranasal administration of glucose-regulating peptides
EP1817048B1 (en) 2004-11-12 2014-02-12 Novo Nordisk A/S Stable formulations of insulinoptropic peptides
KR20070094909A (en) 2004-12-02 2007-09-27 도만티스 리미티드 Bispecific domain ant1bodies targeting serum albumin and glp-1 or pyy
WO2007061434A2 (en) * 2005-11-10 2007-05-31 Nastech Pharmaceutical Company Inc. A pharmaceutical formulation of glp-1 and its use for treating a metabolic syndrome
SG189682A1 (en) 2008-03-31 2013-05-31 Glaxo Group Ltd Drug fusions and conjugates
TW201100104A (en) 2009-03-27 2011-01-01 Glaxo Group Ltd Drug fusions and conjugates
US20120276098A1 (en) 2009-09-30 2012-11-01 Bruce Hamilton Drug fusions and conjugates with extended half life
WO2012136792A2 (en) 2011-04-07 2012-10-11 Glaxo Group Limited Cck compositions
WO2012136790A1 (en) 2011-04-07 2012-10-11 Glaxo Group Limited Compositions comprising fusion proteins or conjugates with an improved half -life
JP2015500823A (en) 2011-12-09 2015-01-08 ノヴォ ノルディスク アー／エス GLP-1 agonist
GB201308753D0 (en) * 2013-05-15 2013-06-26 Stichting Nl Kanker Inst Compounds and their use in therapy
PL3474820T3 (en) 2017-08-24 2024-05-13 Novo Nordisk A/S Glp-1 compositions and uses thereof
EP4106724A1 (en) 2020-02-18 2022-12-28 Novo Nordisk A/S Glp-1 compositions and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ222907A (en) * 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
EP0458894B1 (en) * 1989-02-17 1996-05-15 The Liposome Company, Inc. Lipid excipient for nasal delivery and topical application
GB8918879D0 (en) * 1989-08-18 1989-09-27 Danbiosyst Uk Pharmaceutical compositions
JP3262329B2 (en) * 1990-01-24 2002-03-04 アイ． バックレイ，ダグラス GLP-1 analog useful for the treatment of diabetes

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU671117B2 (en) * 1992-06-15 1996-08-15 Scios Inc. Glucagon-like peptide and insulinotropin derivatives

Also Published As

Publication number Publication date
KR950700754A (en) 1995-02-20
EP0631504A1 (en) 1995-01-04
WO1993018785A1 (en) 1993-09-30
JPH07504669A (en) 1995-05-25
DK36492D0 (en) 1992-03-19

Similar Documents

Publication Publication Date Title
AU3888793A (en) Novel medicament
AU696232B2 (en) Syringe
AU4166393A (en) Auto-reclosers
AU7085594A (en) Syringe
AU3561193A (en) TNF-muteins
AU3991693A (en) Pyrazinoindoles
AU7961094A (en) Picosulphate dosage form
AU4177593A (en) Benzophenonehydrazones
AU685767B2 (en) Substituted benzazepinones
AU3042892A (en) Rockbolt
AU3950193A (en) Cannula
AU4219793A (en) Syringe
AU3542993A (en) Pharmaceutical compounds
AU3263493A (en) Tonometer
AU4156393A (en) Heterocyclyltriazolinones
AU4918790A (en) Medicament
AU4348493A (en) Inhaler
AU664253B2 (en) Photo-deviometer
AU3461693A (en) Saddle-cloth
AU3562193A (en) Morpholin- and thiomorpholin-4-ylamides
AU5737494A (en) Human thrombospondin-4
AU4164793A (en) Heterocyclyltriazolinones
AU4632493A (en) Weathershed
AU4864693A (en) Alkoxymethyl-substituted pyridonebiphenyls
AU3185693A (en) Pyrrolylbenzodiazepinones